TY - JOUR
AU - The COVID-19 Clinical Research Coalition
PY - 2023
DA - July
TI - Pandemics move faster than funders
JO - The Lancet
EP - 367
VL - 402
IS - 10399
DO - https://doi.org/10.1016/S0140-6736(23)01282-5
AB - The COVID-19 pandemic has been marked by inequity between high-income and low-income countries and consequent delays in the availability of diagnostics, drugs, and vaccines. Research has been important in guiding the pandemic response, but funding for locally relevant research in low-resource settings (LRSs) has been inadequate. Limited funding for LRSs meant that research institutions in high-income countries led the way. When research was conducted in LRSs, these were sites rather than lead-research institutions. There has been much talk about equity in the pandemic response, but equity was not evident in the allocation of research funding. In 2020, COVID-19 research received 78% (US$3874 million) of global research and development funding for emerging infectious diseases, dwarfing previous funding for pandemic response.Despite this huge financial investment, LRS researchers found obtaining the rapid funding needed to respond to a fast-moving threat difficult or impossible unless they worked with a high-income lead-research institution. Only 5·5% ($434 million) of the $7885 million allocated in 2020 and 2021 to fund COVID-19 research and development was granted to support research based in low-income and middle-income countries.
PB - Elsevier
UR - http://hdl.handle.net/10023/29086
KW - Coronavirus (COVID-19)
ER